AMRN Amarin Corporation plc

European equities traded in the US as American depositary receipts were tracking modestly higher lat

Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.

European equities traded in the US as American depositary receipts were trending lower late Thursday

Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.

European equities traded in the US as American depositary receipts were trending slightly higher lat

European equities traded in the US as American depositary receipts were tracking lower late Wednesda

Amarin Corporation plc (NASDAQ:AMRN) will present new REDUCE-IT and EPA analyses at the European Society of Cardiology Congress 2026, adding further research around icosapent ethyl, cardiovascular risk factors and potential mechanisms associated with eicosapentaenoic acid. The presentations, scheduled for August 28 through August 30 during the Munich conference, will examine areas including treatment adherence, longer-term outcomes, lipoprotein(a), coagulation biomarkers and cellular pathways re

European equities traded in the US as American depositary receipts were edging lower late Wednesday

Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.

Amarin narrows losses while expanding global market reach across 22 countries.

Amarin Corp PLC (AMRN) showcases international expansion and cost management success despite facing revenue declines and competitive pressures.

AMRN surpasses Q2 earnings estimates despite lower revenues, as cost cuts, rising demand and global partner-driven growth shape its ongoing transformation.

European equities traded in the US as American depositary receipts eased late Wednesday morning with

Strong international demand growth and lower operating expenses supported improved profitability metrics as Amarin reaffirmed confidence in its global commercialization strategy. Key Investor TakeawaysAmarin (NASDAQ:AMRN) reported strong international in-market demand growth, with partner network sales increasing 59% year over year despite lower reported revenue.

Amarin (NASDAQ:AMRN) said its second-quarter results reflected progress in its dual commercial strategy, which combines a company-managed U.S. business with partnered commercialization internationally. Management highlighted growing demand for VASCEPA in Europe, cost reductions from a completed rest

Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.

SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.